Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China

// Yanru Zhang 1, * , Yueyun Wang 2, * , Li Liu 1 , Chun Guo 1 , Zhihua Liu 2 , Shaofa Nie 1 1 Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, P.R. China 2 Shenzhen Maternity and Child Health Hospitals, 518000 Shenzhen, Guangdong, P. R. China * These authors contributed equally to this work Correspondence to: Shaofa Nie, email: sf_nie@mails.tjmu.edu.cn Zhihua Liu, email: drzhliu@163.com Keywords: human papillomavirus, prevalence, genotype, cervical screening, China Received: May 09, 2016     Accepted: July 28, 2016     Published: August 22, 2016 ABSTRACT We conducted a cross-sectional analysis to assess the distribution of human papillomavirus (HPV) types and explored an acceptable strategy for cervical screening in Shenzhen, China. A total of 2717 individuals ranging in age from 30–59 years were recruited. Clinical sensitivity and specificity as well as positive (PPV) and negative (NPV) predictive values were estimated. A triage strategy was regarded as acceptable when the NPV was at least 98.0%. 432 (15.9%) participants presented HPV positive. The five most prevalent HPV types were HPV52 (22.9%), HPV16 (12.7%), HPV53 (10.0%), HPV51 (8.6%), and HPV58 (8.1%). The CIN2+ risks for each HPV type were 40.0% for HPV33, 32.4% for HPV16, 18.2% for HPV58, 13.3% for HPV56, and 11.1% for HPV68 in descending order. Baseline cytology testing combined with HPV16/33/52/58 genotyping met the NPV thresholds at 98.6% with a PPV of 17.9%, demonstrating excellent clinical performance for detecting HPV types in CIN2+ patients. In conclusion, triaging HPV-positive women by baseline cytology combined with HPV16/58/33/52 genotyping is an acceptable strategy for cervical cancer screening in Shenzhen, China.